What question did this study set out to answer?

To assess the post-licensure safety of the 20-valent pneumococcal conjugate vaccine compared to a historical control.

Preliminary results of 20-valent pneumococcal conjugate vaccine (PCV20) monitoring in children through 24 months of age in the Vaccine Safety Datalink

View Full Paper

Ask AI

Bookmark

To assess the post-licensure safety of the 20-valent pneumococcal conjugate vaccine compared to a historical control.
Utilized surveillance data from the Vaccine Safety Datalink
Monitored adverse events following vaccination with PCV20 and PCV13
Employed Poisson regression models stratified by age and demographics for data analysis
No significant signals for nine of ten adverse events monitored
Identified a significant finding for urticaria following PCV20 dose 4, with a rate ratio of 4.14
Ongoing medical record review to validate automated case reports

No takes yet. Share an insight, caveat, or question.

Surveillance reports an increased rate ratio for urticaria after PCV20 dose 4 in children, highlighting safety concerns.

Kenigsberg et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark